November 20th 2024
This approval is the fifth overall for bimekizumab (Bimzelx; UCB Pharma) in the US, and they all have come in the last 13 months.
Join us as Dr. Iltefat Hamzavi shares insights into hidradenitis suppurativa. Learn about its signs, symptoms, differential diagnosis, and treatment strategies, as Dr. Hamzavi highlights the impact on patients and families.